BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 7914482)

  • 21. Recruitment of host CD8+ T cells by tumor-infiltrating lymphocytes and recombinant interleukin-2 during adoptive immunotherapy of cancer.
    Burger UL; Chang MP; Goedegebuure PS; Eberlein TJ; Adams-Hodgins S
    Surgery; 1995 Mar; 117(3):325-33. PubMed ID: 7878540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.
    Jackaman C; Bundell CS; Kinnear BF; Smith AM; Filion P; van Hagen D; Robinson BW; Nelson DJ
    J Immunol; 2003 Nov; 171(10):5051-63. PubMed ID: 14607902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spontaneous immune rejection of intraocular tumors in mice.
    Niederkorn JY; Meunier PC
    Invest Ophthalmol Vis Sci; 1985 Jun; 26(6):877-84. PubMed ID: 3924853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Local T helper cell signals by lymphocytes infiltrating intraocular tumors.
    Ksander BR; Acevedo J; Streilein JW
    J Immunol; 1992 Mar; 148(6):1955-63. PubMed ID: 1531848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice.
    Manning TC; Rund LA; Gruber MM; Fallarino F; Gajewski TF; Kranz DM
    J Immunol; 1997 Nov; 159(10):4665-75. PubMed ID: 9366389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunologic evaluation of spontaneous regression of an intraocular murine melanoma.
    Knisely TL; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1990 Feb; 31(2):247-57. PubMed ID: 2154414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Failure of infiltrating precursor cytotoxic T cells to acquire direct cytotoxic function in immunologically privileged sites.
    Ksander BR; Streilein JW
    J Immunol; 1990 Oct; 145(7):2057-63. PubMed ID: 1975822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice.
    Yoshimura A; Shiku H; Nakayama E
    J Immunol; 1993 Jun; 150(11):4900-10. PubMed ID: 8496592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD4-positive helper T lymphocytes mediate mouse cardiac allograft rejection independent of donor alloantigen specific cytotoxic T lymphocytes.
    Bishop DK; Chan S; Li W; Ensley RD; Xu S; Eichwald EJ
    Transplantation; 1993 Oct; 56(4):892-7. PubMed ID: 8212213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A direct comparison of rejection by CD8 and CD4 T cells in a transgenic model of allotransplantation.
    Porrett PM; Lee MK; Lian MM; Wang J; Caton AJ; Deng S; Markmann JF; Moore DJ
    Arch Immunol Ther Exp (Warsz); 2008; 56(3):193-200. PubMed ID: 18512028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune rejection of metastases arising from intraocular tumors in mice.
    Niederkorn JY; Knisely TL; Mayhew E
    Invest Ophthalmol Vis Sci; 1986 Sep; 27(9):1355-61. PubMed ID: 3091527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T-cell-mediated immune responses in alloepithelial rejection after murine keratoepithelioplasty.
    Miyazaki D; Inoue Y; Yao YF; Okada AA; Shimomura Y; Hayashi K; Tano Y; Ohashi Y
    Invest Ophthalmol Vis Sci; 1999 Oct; 40(11):2590-7. PubMed ID: 10509654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
    Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
    J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Depletion of CD4(+)CD25(high) regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy.
    Xu L; Xu W; Jiang Z; Zhang F; Chu Y; Xiong S
    Cancer Biol Ther; 2009 Jan; 8(1):66-72. PubMed ID: 19029829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The therapeutic efficacy of murine anti-tumor T cells: freshly isolated T cells are more therapeutic than T cells expanded in vitro.
    Evans R; Kamdar SJ; Duffy TM; Krupke DM; Fuller JA; Dudley ME
    Anticancer Res; 1995; 15(2):441-7. PubMed ID: 7763019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intrathymic alloantigen-mediated, tolerant, completely major histocompatibility complex-mismatched mouse hearts are specifically rejected by adoptively transferred anti-class I L(d+)-specific 2C cells.
    Otomo N; Motoyama K; Yu S; Shimizu Y; Margenthaler J; Tu F; Flye MW
    Surgery; 2000 Aug; 128(2):206-12. PubMed ID: 10922993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity.
    Dorothée G; Vergnon I; Menez J; Echchakir H; Grunenwald D; Kubin M; Chouaib S; Mami-Chouaib F
    J Immunol; 2002 Jul; 169(2):809-17. PubMed ID: 12097384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix.
    Santin AD; Bellone S; Palmieri M; Bossini B; Roman JJ; Cannon MJ; Bignotti E; Canè S; Pecorelli S
    Gynecol Oncol; 2003 May; 89(2):271-80. PubMed ID: 12713991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells.
    Walker PR; Calzascia T; Schnuriger V; Scamuffa N; Saas P; de Tribolet N; Dietrich PY
    J Immunol; 2000 Sep; 165(6):3128-35. PubMed ID: 10975826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction.
    Boonman ZF; van Mierlo GJ; Fransen MF; Franken KL; Offringa R; Melief CJ; Jager MJ; Toes RE
    J Immunol; 2004 Feb; 172(3):1567-74. PubMed ID: 14734736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.